Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Raphael Pharmaceutical Inc. (RAPH) had Consolidated Net Income/Loss of $-0.22M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-0.22M |
|
-- |
|
-- |
|
$0.20M |
|
$-0.20M |
|
$-0.02M |
|
$-0.22M |
|
$-0.22M |
|
$-0.22M |
|
$-0.22M |
|
|
Consolidated Net Income/Loss |
$-0.22M |
$-0.22M |
|
$-0.20M |
|
$-0.20M |
|
20.18M |
|
20.18M |
|
$-0.01 |
|
$-0.01 |
|
| Balance Sheet Financials | |
$0.01M |
|
$0.00M |
|
$0.00M |
|
$0.01M |
|
$1.89M |
|
-- |
|
-- |
|
$1.89M |
|
$-1.89M |
|
$-1.89M |
|
$-1.89M |
|
20.18M |
|
| Cash Flow Statement Financials | |
$-0.04M |
|
-- |
|
-- |
|
$0.04M |
|
$0.00M |
|
$-0.04M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.00 |
|
-- |
|
-- |
|
-- |
|
-0.02 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-0.04M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
11.83% |
|
11.83% |
|
-3185.71% |
|
11.83% |
|
$-0.09 |
|
$-0.00 |
|
$-0.00 |
|